Tourmaline Bio

Last week was Thyroid Eye Disease (TED) Awareness Week. In TED, the immune system causes inflammation and swelling behind the eye and, in rare cases, can lead to blindness. Tourmaline is committed to partnering with the community, including Prevent Blindness, to provide resources and support to empower patients with the knowledge to manage their condition. Visit the website: https://bit.ly/3CKHV54

In honor of Thyroid Eye Disease (TED) Awareness Week, we’re spotlighting our partnership with MyHealthTeam. This collaboration connects people living with TED to a supportive community and provides access to medically-reviewed information to help them along their journey. If you or someone you know has TED, remember: there’s a community here for you. Connect with others and find support at TEDHealthTeam.com

Tourmaline will join top minds in cardiovascular health at the American Heart Association's Scientific Sessions, November 16-18, in Chicago. We're excited to share insights, exchange ideas, and be part of the latest innovations in heart health. #AHA24.

Set your calendars for Tourmaline's Investor Day on December 10 at 10 a.m. ET. Join us virtually to hear from our leadership team and special guest, Dr. Marc Bonaca, a cardiologist and vascular medicine specialist.?? ? Register now to stay updated on our transformative work in immune and inflammatory diseases: https://bit.ly/3Ydvy8S

Join our CEO, Sandeep Kulkarni, for a fireside chat during the Guggenheim Securities Healthcare Innovation Conference at 1:30 pm ET on November 12. He will share Tourmaline’s strategic vision and clinical progress made in 2024. Register to watch, or find the replay here: https://bit.ly/3Ydvy8S

Our CEO, Sandeep Kulkarni, joined the Truist Securities BioPharma Symposium panel, “Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle Illnesses,” yesterday. He shared his insights into advanced treatment strategies for high-risk cardiovascular disease. The panel discussion highlighted the therapeutic potential of targeting inflammation to reduce cardiovascular risk—a focus central to Tourmaline’s strategy targeting IL-6 inhibition to address the inflammatory pathways driving major adverse events in high-risk patients. Thank you, Kripa Devarakonda, Ph.D., for moderating.

We’ve just released our Q3 2024 financial results, highlighting our latest achievements and upcoming clinical milestones. Take a look at our progress and what’s next for Tourmaline. ?? https://bit.ly/4hGw8Vg

ICYMI: Our recent investor webinar with Dr. Dipender Gill covered the genetic underpinnings of IL-6 inhibition and its impact on developing treatments for high-risk cardiovascular patients. The replay, which captures how genetic insights are driving new therapeutic strategies, can be found here: https://bit.ly/3Ydvy8S

Thank you to everyone who joined our investor webinar with Dr. Dipender Gill of Sequoia Genetics. During the session, Dr. Gill shared key insights into the role of genetic validation in targeting IL-6 inhibition for cardiovascular disease. His discussion on leveraging human genetic data to refine treatment approaches highlighted the potential to better manage high-risk patients and accelerate innovation in therapeutic development. The replay and presentation deck can be found here: https://bit.ly/3Ydvy8S

Join us for an in-depth investor webinar featuring Dr. Dipender Gill, CEO and Founder of Sequoia Genetics on November 1st at 9:30 AM ET. He will share his key insights on how human genetic studies are driving innovative approaches for treating high-risk cardiovascular patients, such as IL-6 inhibition. With cardiovascular disease being one of the leading global health challenges, understanding the genetic drivers of cardiovascular risk is crucial to developing therapies that go beyond conventional treatments. Register now to gain valuable insights from an expert in cardiovascular genetics: https://bit.ly/3zOmejF